CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Torti Frank President and Vant Chair | Other disposition | −173,683 | $40.43 | $7.0M | 13,322,210 |
| 2026-11-10 | Torti Frank President and Vant Chair | Other disposition | −218,369 | $41.13 | $9.0M | 13,103,841 |
| 2026-11-10 | Gline Matthew CEO | Other disposition | −25,841 | $40.43 | $1.0M | 16,523,295 |
| 2026-11-10 | Gline Matthew CEO | Other disposition | −32,490 | $41.13 | $1.3M | 16,490,805 |
| 2026-11-10 | Sukhatme Mayukh President & CIO | Other disposition | −26,152 | $40.43 | $1.1M | 18,537,732 |
| 2026-11-10 | Sukhatme Mayukh President & CIO | Other disposition | −32,882 | $41.13 | $1.4M | 18,504,850 |
| 2026-11-10 | Pulik Richard CFO | Option exercise | +125,000 | $3.85 | $481K | 394,681 |
| 2026-11-10 | Pulik Richard CFO | Sale | −125,000 | $41.20 | $5.2M | 269,681 |
| 2026-11-10 | Pulik Richard CFO | Option exercise · Stock Option (Right to Buy) | −125,000 | 615,000 | ||
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −158,194 | $40.44 | $6.4M | 840,960 |
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −29,749 | $41.00 | $1.2M | 811,211 |
| 2026-11-03 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.31 | $7.3M | 999,154 |
| 2026-10-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.59 | $7.3M | 1,199,154 |
| 2026-10-23 | Epperly Melissa B, Director | Grant or award | +513 | 15,467 | ||
| 2026-10-23 | Epperly Melissa B, Director | Shares withheld for taxes | −116 | $36.49 | $4K | 15,351 |
| 2026-10-23 | Oren Ilan Director | Grant or award | +810 | 124,490 | ||
| 2026-10-23 | MOMTAZEE JAMES C Director | Grant or award | +383 | 112,342 | ||
| 2026-10-23 | MOMTAZEE JAMES C Director | Shares withheld for taxes | −77 | $36.49 | $3K | 112,265 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −185,856 | $35.09 | $6.5M | 1,413,298 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −14,144 | $35.42 | $501K | 1,399,154 |
Page 2 of 29 · 570 trades